Comments
Loading...

Denali Therapeutics Analyst Ratings

DNLINASDAQ
Logo brought to you by Benzinga Data
$14.76
0.332.29%
At close: -
$14.76
0.000.00%
After Hours: 4:00 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$87.00
Lowest Price Target1
$24.00
Consensus Price Target1
$38.79

Denali Therapeutics Analyst Ratings and Price Targets | NASDAQ:DNLI | Benzinga

Denali Therapeutics Inc has a consensus price target of $38.79 based on the ratings of 22 analysts. The high is $87 issued by HC Wainwright & Co. on February 28, 2025. The low is $24 issued by JP Morgan on January 7, 2025. The 3 most-recent analyst ratings were released by B of A Securities, Morgan Stanley, and B. Riley Securities on March 10, 2025, March 7, 2025, and March 5, 2025, respectively. With an average price target of $32 between B of A Securities, Morgan Stanley, and B. Riley Securities, there's an implied 116.80% upside for Denali Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Dec 24
5
Jan
2
Feb
4
Mar
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.3
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

B of A Securities
Morgan Stanley
B. Riley Securities
Oppenheimer
HC Wainwright & Co.

1calculated from analyst ratings

Analyst Ratings for Denali Therapeutics

Buy NowGet Alert
03/10/2025Buy Now89.7%B of A Securities
Tazeen Ahmad55%
$30 → $28MaintainsBuyGet Alert
03/07/2025Buy Now123.58%Morgan Stanley
Matthew Harrison60%
$41 → $33Assumes → OverweightGet Alert
03/05/2025Buy Now137.13%B. Riley Securities
Mayank Mamtani71%
$38 → $35ReiteratesBuy → BuyGet Alert
03/03/2025Buy Now184.55%Oppenheimer
Jay Olson62%
$50 → $42MaintainsOutperformGet Alert
02/28/2025Buy Now489.43%HC Wainwright & Co.
Andrew Fein57%
$80 → $87MaintainsBuyGet Alert
02/11/2025Buy Now110.03%Deutsche Bank
David Hoang42%
→ $31Initiates → BuyGet Alert
01/28/2025Buy Now171%Goldman Sachs
Salveen Richter52%
$45 → $40MaintainsBuyGet Alert
01/07/2025Buy Now62.6%JP Morgan
Jessica Fye68%
$28 → $24MaintainsOverweightGet Alert
01/07/2025Buy Now489.43%HC Wainwright & Co.
Andrew Fein57%
$90 → $87MaintainsBuyGet Alert
01/07/2025Buy Now110.03%Baird
Joel Beatty69%
→ $31Initiates → OutperformGet Alert
01/03/2025Buy Now—William Blair
Sarah Schram8%
—Initiates → OutperformGet Alert
12/16/2024Buy Now150.68%Stifel
Paul Mattels7%
→ $37UpgradeHold → BuyGet Alert
11/07/2024Buy Now509.76%HC Wainwright & Co.
Andrew Fein57%
$90 → $90ReiteratesBuy → BuyGet Alert
11/01/2024Buy Now204.88%Jefferies
Michael Yee56%
$40 → $45MaintainsBuyGet Alert
10/11/2024Buy Now89.7%JP Morgan
Jessica Fye68%
$29 → $28MaintainsOverweightGet Alert
10/10/2024Buy Now—Raymond James
Danielle Brill43%
—Reinstates → Market PerformGet Alert
09/09/2024Buy Now137.13%Cantor Fitzgerald
Charles Duncan72%
$35 → $35ReiteratesOverweight → OverweightGet Alert
09/04/2024Buy Now509.76%HC Wainwright & Co.
Andrew Fein57%
$90 → $90ReiteratesBuy → BuyGet Alert
09/04/2024Buy Now96.48%B of A Securities
Tazeen Ahmad55%
$25 → $29MaintainsBuyGet Alert
08/15/2024Buy Now509.76%HC Wainwright & Co.
Andrew Fein57%
$90 → $90ReiteratesBuy → BuyGet Alert
08/05/2024Buy Now509.76%HC Wainwright & Co.
Andrew Fein57%
$95 → $90MaintainsBuyGet Alert
08/02/2024Buy Now116.8%Citigroup
David Hoang42%
$26 → $32MaintainsBuyGet Alert
08/02/2024Buy Now76.15%Wedbush
Laura Chico48%
$30 → $26MaintainsOutperformGet Alert
07/10/2024Buy Now96.48%JP Morgan
Jessica Fye68%
$28 → $29MaintainsOverweightGet Alert
05/08/2024Buy Now543.63%HC Wainwright & Co.
Andrew Fein57%
$95 → $95ReiteratesBuy → BuyGet Alert
05/08/2024Buy Now103.25%Wedbush
Laura Chico48%
$31 → $30MaintainsOutperformGet Alert
05/08/2024Buy Now49.05%Stifel
Paul Mattels7%
$26 → $22MaintainsHoldGet Alert
04/09/2024Buy Now116.8%UBS
Esther Rajavelu34%
$70 → $32MaintainsBuyGet Alert
02/29/2024Buy Now238.75%Goldman Sachs
Salveen Richter52%
$73 → $50MaintainsBuyGet Alert
02/28/2024Buy Now110.03%Wedbush
Laura Chico48%
$31 → $31ReiteratesOutperform → OutperformGet Alert
02/28/2024Buy Now543.63%HC Wainwright & Co.
Andrew Fein57%
$105 → $95MaintainsBuyGet Alert
02/22/2024Buy Now611.38%HC Wainwright & Co.
Andrew Fein57%
$105 → $105ReiteratesBuy → BuyGet Alert
12/13/2023Buy Now116.8%Citigroup
David Hoang42%
→ $32Initiates → BuyGet Alert
11/20/2023Buy Now89.7%JP Morgan
Jessica Fye68%
→ $28Reinstates → OverweightGet Alert
11/08/2023Buy Now110.03%Wedbush
Laura Chico48%
→ $31ReiteratesOutperform → OutperformGet Alert
10/24/2023Buy Now137.13%Cantor Fitzgerald
Charles Duncan72%
$85 → $35Assumes → OverweightGet Alert
09/06/2023Buy Now157.45%B. Riley Securities
Mayank Mamtani71%
→ $38Initiates → BuyGet Alert
08/31/2023Buy Now611.38%HC Wainwright & Co.
Andrew Fein57%
→ $105ReiteratesBuy → BuyGet Alert
08/31/2023Buy Now475.88%Cantor Fitzgerald
Charles Duncan72%
→ $85ReiteratesOverweight → OverweightGet Alert
08/22/2023Buy Now475.88%Cantor Fitzgerald
Charles Duncan72%
→ $85ReiteratesOverweight → OverweightGet Alert
08/10/2023Buy Now475.88%Cantor Fitzgerald
Charles Duncan72%
→ $85ReiteratesOverweight → OverweightGet Alert
08/09/2023Buy Now110.03%Wedbush
Laura Chico48%
$37 → $31MaintainsOutperformGet Alert
08/09/2023Buy Now611.38%HC Wainwright & Co.
Andrew Fein57%
→ $105ReiteratesBuy → BuyGet Alert
06/22/2023Buy Now475.88%Cantor Fitzgerald
Charles Duncan72%
→ $85ReiteratesOverweight → OverweightGet Alert
06/21/2023Buy Now611.38%HC Wainwright & Co.
Andrew Fein57%
→ $105ReiteratesBuy → BuyGet Alert
06/06/2023Buy Now360.7%Oppenheimer
Jay Olson62%
$70 → $68MaintainsOutperformGet Alert
05/09/2023Buy Now150.68%Wedbush
Laura Chico48%
$38 → $37MaintainsOutperformGet Alert
05/09/2023Buy Now611.38%HC Wainwright & Co.
Andrew Fein57%
→ $105Reiterates → BuyGet Alert
04/12/2023Buy Now326.83%Morgan Stanley
Matthew Harrison60%
$61 → $63MaintainsOverweightGet Alert
03/02/2023Buy Now374.25%Oppenheimer
Jay Olson62%
$85 → $70MaintainsOutperformGet Alert
03/01/2023Buy Now313.28%Morgan Stanley
Matthew Harrison60%
$65 → $61MaintainsOverweightGet Alert
02/28/2023Buy Now238.75%Evercore ISI Group
Joshua Schimmer43%
$80 → $50MaintainsOutperformGet Alert
02/28/2023Buy Now611.38%HC Wainwright & Co.
Andrew Fein57%
→ $105Reiterates → BuyGet Alert
02/28/2023Buy Now157.45%Wedbush
Laura Chico48%
$46 → $38MaintainsOutperformGet Alert
02/23/2023Buy Now611.38%HC Wainwright & Co.
Andrew Fein57%
→ $105Reiterates → BuyGet Alert
01/30/2023Buy Now238.75%SVB Leerink
Marc Goodman74%
→ $50Initiates → OutperformGet Alert
01/25/2023Buy Now340.38%Morgan Stanley
Matthew Harrison60%
$60 → $65MaintainsOverweightGet Alert
12/05/2022Buy Now—Cowen & Co.
Brendan Smith36%
—Initiates → OutperformGet Alert
11/08/2022Buy Now306.5%Morgan Stanley
Matthew Harrison60%
$67 → $60MaintainsOverweightGet Alert
11/02/2022Buy Now171%B of A Securities
Avikal Malik3%
→ $40Initiates → BuyGet Alert
06/23/2022Buy Now164.23%Berenberg
Caroline Palomeque60%
→ $39Initiates → BuyGet Alert
05/24/2022Buy Now455.56%Goldman Sachs
Salveen Richter52%
$99 → $82MaintainsBuyGet Alert

FAQ

Q

What is the target price for Denali Therapeutics (DNLI) stock?

A

The latest price target for Denali Therapeutics (NASDAQ:DNLI) was reported by B of A Securities on March 10, 2025. The analyst firm set a price target for $28.00 expecting DNLI to rise to within 12 months (a possible 89.70% upside). 28 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Denali Therapeutics (DNLI)?

A

The latest analyst rating for Denali Therapeutics (NASDAQ:DNLI) was provided by B of A Securities, and Denali Therapeutics maintained their buy rating.

Q

When was the last upgrade for Denali Therapeutics (DNLI)?

A

The last upgrade for Denali Therapeutics Inc happened on December 16, 2024 when Stifel raised their price target to $37. Stifel previously had a hold for Denali Therapeutics Inc.

Q

When was the last downgrade for Denali Therapeutics (DNLI)?

A

There is no last downgrade for Denali Therapeutics.

Q

When is the next analyst rating going to be posted or updated for Denali Therapeutics (DNLI)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Denali Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Denali Therapeutics was filed on March 10, 2025 so you should expect the next rating to be made available sometime around March 10, 2026.

Q

Is the Analyst Rating Denali Therapeutics (DNLI) correct?

A

While ratings are subjective and will change, the latest Denali Therapeutics (DNLI) rating was a maintained with a price target of $30.00 to $28.00. The current price Denali Therapeutics (DNLI) is trading at is $14.76, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch